Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shaughnessy

Showing results (141-150 of 194) with videos related to

Pageof 20
Sort By:
Blood Advances|November 2, 2022
AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activityTimon A Bloedjes, Guus de Wilde, Gerarda H Khan, et al.
The Journal of Clinical Investigation|October 26, 2023
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesionsFumou Sun, Yan Cheng, Jin-Ran Chen, et al.
British Journal of Haematology|May 8, 2013
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activityMoshe E Gatt, Kohichi Takada, Mala Mani, et al.
Blood|May 22, 2008
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalitiesBart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, et al.
Blood Cancer Journal|March 5, 2024
Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencingJian-Rong Li, Shahram Arsang-Jang, Yan Cheng, et al.
Research Square|May 20, 2024
Cystatin M/E ameliorates bone resorption through increasing osteoclastic cell estrogen influxDongzheng Gai, Perry C Caviness, Oxana P Lazarenko, et al.
Cancers|March 13, 2025
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone ResorptionDongzheng Gai, Perry C Caviness, Oxana P Lazarenko, et al.
British Journal of Haematology|October 28, 2008
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantationJumei Shi, Guido Tricot, Susann Szmania, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2012
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1Christoph J Heuck, Jackie Szymonifka, Emily Hansen, et al.
Nature Genetics|February 1, 1996
Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemiaT Nakamura, D A Largaespada, M P Lee, et al.
Pageof 20

Showing results (141-150 of 194) with videos related to

Sort By:
Pageof 20
Blood Advances|November 2, 2022
AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activityTimon A Bloedjes, Guus de Wilde, Gerarda H Khan, et al.
The Journal of Clinical Investigation|October 26, 2023
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesionsFumou Sun, Yan Cheng, Jin-Ran Chen, et al.
British Journal of Haematology|May 8, 2013
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activityMoshe E Gatt, Kohichi Takada, Mala Mani, et al.
Blood|May 22, 2008
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalitiesBart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, et al.
Blood Cancer Journal|March 5, 2024
Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencingJian-Rong Li, Shahram Arsang-Jang, Yan Cheng, et al.
Research Square|May 20, 2024
Cystatin M/E ameliorates bone resorption through increasing osteoclastic cell estrogen influxDongzheng Gai, Perry C Caviness, Oxana P Lazarenko, et al.
Cancers|March 13, 2025
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone ResorptionDongzheng Gai, Perry C Caviness, Oxana P Lazarenko, et al.
British Journal of Haematology|October 28, 2008
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantationJumei Shi, Guido Tricot, Susann Szmania, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2012
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1Christoph J Heuck, Jackie Szymonifka, Emily Hansen, et al.
Nature Genetics|February 1, 1996
Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemiaT Nakamura, D A Largaespada, M P Lee, et al.
Pageof 20